Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 10, pp 2653–2661 | Cite as

A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation

  • Qin Yang
  • Junke Wang
  • Fei Liu
  • Wenjie Ma
  • Haijie Hu
  • Congdun Ran
  • Fuyu Li
  • Qiuwei Pan
Original Article

Abstract

Background

Benign biliary stricture (BBS) is highly refractory. Currently, there is no effective strategy for prevention of BBS recurrence. The aim of this study is to establish a novel BBS rabbit model and to investigate the efficacy of biliary infusion with anti-proliferative medications for treating BBS.

Method

A BBS model was established via surgical injury and biliary infection. The biliary infusion tube was inserted into the common bile duct via the stump of cystic duct after cholecystectomy. Biliary infusions with Rapamycin, Pirfenidone and Fasudil were performed daily during the 4 weeks following the surgery. The wall thickness and luminal area of the bile duct were assessed.

Results

All rabbits formed BBS after surgery. The mortality rate was 13% (8/60) and tube withdrawal rate was 4% (2/48). The thickness of the bile duct wall was significantly reduced; whereas the luminal area of the bile duct was dramatically enlarged in the Rapamycin or the Pirfenidone treated group, compared to the saline treated group. Furthermore, the local treatment significantly decreased the levels of proliferation makers, including PCNA, Collagen I and fibrogenic mediators, including ACTA2 and TGF-beta.

Conclusion

We have established a novel animal model for BBS formation. We have further demonstrated that biliary infusion with Rapamycin or Pirfenidone limits the biliary strictures through inhibiting the proliferation of the bile duct wall in this model. This may represent a new avenue for preventing biliary restenosis.

Keywords

Benign biliary stricture Animal model Biliary infusion Local anti-proliferation Recurrence 

Notes

Acknowledgments

We thank the China Scholarship Council for funding Ph.D. fellowships to Q.Y. (201706240113). We deeply appreciate the help of language revision by Lennart V. D. Velden, and kind suggestions for improving figures by Xumin Ou.

Author’s contribution

FL designed this research; JW, HH, FL and CR contributed to the acquisition, analysis and interpretation of the data; QY and WM performed the experimental operation; QY drafted this article; QP and FL revised this manuscript and gave the final approval of the version to be published.

Funding

This research was supported by the Science and Technology Support Project of Sichuan Province (Nos. 2018SY0019 and 2014SZ0191).

Compliance with ethical standards

Conflict of interest

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Animal care and use

The animal protocol was designed to minimize pain or discomfort to the animals. The animals were acclimatized to laboratory conditions (23 °C, 12 h/12 h/light/dark, 50% humidity, ad libitum access to food and water) for 2 weeks prior to experimentation. Intragastric gavage administration was carried out with conscious animals, using straight gavage needles appropriate for the animal size. All animals were euthanized by barbiturate overdose (intravenous injection, 150 mg/kg pentobarbital sodium) for tissue collection.

Institutional animal care and use committee

All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Sichuan University.

Supplementary material

10620_2018_5118_MOESM1_ESM.docx (20 mb)
Supplementary material 1 (DOCX 20512 kb)

References

  1. 1.
    Altman A, Zangan SM. Benign biliary strictures. Semin Intervent Radiol. 2016;33:297–306.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kaffes AJ. Management of benign biliary strictures: current status and perspective. J Hepatobiliary Pancreat Sci. 2015;22:657–663.CrossRefPubMedGoogle Scholar
  3. 3.
    Zepeda-Gomez S, Baron TH. Benign biliary strictures: current endoscopic management. Nat Rev Gastroenterol Hepatol. 2011;8:573–581.CrossRefPubMedGoogle Scholar
  4. 4.
    Hu B, Sun B, Cai Q, et al. Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures. Gastrointest Endosc. 2017;86:44–58.CrossRefPubMedGoogle Scholar
  5. 5.
    Mauri G, Michelozzi C, Melchiorre F, et al. Benign biliary strictures refractory to standard bilioplasty treated using polydoxanone biodegradable biliary stents: retrospective multicentric data analysis on 107 patients. Eur Radiol. 2016;26:4057–4063.CrossRefPubMedGoogle Scholar
  6. 6.
    Visrodia KH, Tabibian JH, Baron TH. Endoscopic management of benign biliary strictures. World J Gastrointest Endosc. 2015;7:1003–1013.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Deviere J. Benign biliary strictures and leaks. Gastrointest Endosc Clin N Am. 2015;25:713–723.CrossRefPubMedGoogle Scholar
  8. 8.
    Weber A, Zellner S, Wagenpfeil S, et al. Long-term follow-up after endoscopic stent therapy for benign biliary strictures. J Clin Gastroenterol. 2014;48:88–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Geng ZM, Yao YM, Liu QG, Niu XJ, Liu XG. Mechanism of benign biliary stricture: a morphological and immunohistochemical study. World J Gastroenterol. 2005;11:293–295.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Li FY, Cheng NS, Mao H, et al. Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis. World J Surg. 2009;33:2155–2160.CrossRefPubMedGoogle Scholar
  11. 11.
    Li KY, Shi CX, Huang JZ, Tang KL. Tetramethylpyrazine effects on the expression of scar-related genes in rabbit benign biliary stricture fibroblasts. J Coll Physicians Surg Pak. 2016;26:813–817.PubMedGoogle Scholar
  12. 12.
    Liu YK, Li ZH, Liu NZ, et al. Reduced myoelectric activity in the sphincter of Oddi in a new model of chronic cholangitis in rabbits: an in vivo and in vitro study. Neurogastroenterol Motil. 2010;22(8):927–934. (e238–e929).CrossRefPubMedGoogle Scholar
  13. 13.
    Sievert KD, Selent-Stier C, Wiedemann J, et al. Introducing a large animal model to create urethral stricture similar to human stricture disease: a comparative experimental microscopic study. J Urol. 2012;187:1101–1109.CrossRefPubMedGoogle Scholar
  14. 14.
    Lim KS, Park JK, Jeong MH, et al. Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. J Mater Sci Mater Med. 2016;27:66.CrossRefPubMedGoogle Scholar
  15. 15.
    Chong T, Fu DL, Li HC, et al. Rapamycin inhibits formation of urethral stricture in rabbits. J Pharmacol Exp Ther. 2011;338:47–52.CrossRefPubMedGoogle Scholar
  16. 16.
    Yamaguchi Y, Feghali-Bostwick CA. Role of endostatin in fibroproliferative disorders.-as a candidate for anti-fibrosis therapy. Jpn J Clin Immunol. 2013;36:452–458.CrossRefGoogle Scholar
  17. 17.
    Stahnke T, Kowtharapu BS, Stachs O, et al. Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. PLoS ONE. 2017;12:e0172592.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hasdemir PS, Ozkut M, Guvenal T, et al. Effect of pirfenidone on vascular proliferation, inflammation and fibrosis in an abdominal adhesion rat model. J Investig Surg. 2017;30:26–32.CrossRefGoogle Scholar
  19. 19.
    Olmos-Zuniga JR, Silva-Martinez M, Jasso-Victoria R, et al. Effects of pirfenidone and collagen-polyvinylpyrrolidone on macroscopic and microscopic changes, TGF-beta1 expression, and collagen deposition in an experimental model of tracheal wound healing. Biomed Res Int. 2017;2017:6471071.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Orozco-Perez J, Aguirre-Jauregui O, Salazar-Montes AM, Sobrevilla-Navarro AA, Lucano-Landeros MS, Armendariz-Borunda J. Pirfenidone prevents rat esophageal stricture formation. J Surg Res. 2015;194:558–564.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang K, Guo X, Zhao W, Niu G, Mo X, Fu Q. Application of Wnt pathway inhibitor delivering scaffold for inhibiting fibrosis in urethra strictures. In vitro and in vivo study. Int J Mol Sci. 2015;16:27659–27676.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shenkar R, Shi C, Austin C, et al. RhoA kinase inhibition with Fasudil versus simvastatin in murine models of cerebral cavernous malformations. Stroke. 2017;48:187–194.CrossRefPubMedGoogle Scholar
  23. 23.
    Parsi MA. Common controversies in management of biliary strictures. World J Gastroenterol. 2017;23:1119–1124.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Komiya C, Tanaka M, Tsuchiya K, et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep. 2017;7:44754.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Du J, Paz K, Flynn R, et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. Blood. 2017;129:2570–2580.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wu YH, Li XW, Li WQ, et al. Fluorofenidone attenuates bleomycin-induced pulmonary fibrosis by inhibiting eukaryotic translation initiation factor 3a (eIF3a) in rats. Eur J Pharmacol. 2016;773:42–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Shen C, Peng C, Shen B, et al. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation. Oncotarget. 2016;7:62647–62656.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Li G, Ren J, Hu Q, et al. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-beta signaling in a murine colitis model. Biochem Pharmacol. 2016;117:57–67.CrossRefPubMedGoogle Scholar
  29. 29.
    Chen LP, Zhang QH, Chen G, Qian YY, Shi BY, Dong JH. Rapamycin inhibits cholangiocyte regeneration by blocking interleukin-6-induced activation of signal transducer and activator of transcription 3 after liver transplantation. Liver Transpl. 2010;16:204–214.CrossRefPubMedGoogle Scholar
  30. 30.
    Chen C, Yu JZ, Zhang Q, et al. Role of Rho Kinase and Fasudil on synaptic plasticity in multiple sclerosis. NeuroMol Med. 2015;17:454–465.CrossRefGoogle Scholar
  31. 31.
    Bond JE, Kokosis G, Ren L, Selim MA, Bergeron A, Levinson H. Wound contraction is attenuated by Fasudil inhibition of Rho-associated kinase. Plast Reconstr Surg. 2011;128:438e–450e.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wang L, Wang T, Song M, Pan J. Rho plays a key role in TGF-beta1-induced proliferation and cytoskeleton rearrangement of human periodontal ligament cells. Arch Oral Biol. 2014;59:149–157.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Hepatobiliary SurgeryWest China Hospital of Sichuan UniversityChengduChina
  2. 2.Department of Gastroenterology and Hepatology, Postgraduate School Molecular MedicineErasmus MC-University Medical CenterRotterdamThe Netherlands

Personalised recommendations